cough
reflex
mucociliari
clearanc
foreign
materi
invad
tracheobronchi
tree
local
product
immunoglobulin
iga
igg
ige
mucosa
respiratori
tract
provid
anoth
layer
protect
invad
microb
rel
proport
iga
igg
respiratori
tract
chang
locat
greater
ratio
iga
igg
nasal
mucosa
trachea
bronchial
tree
revers
ratio
alveoli
greater
proport
igg
iga
may
import
protect
viral
infect
neutral
sever
respiratori
virus
rhinoviru
influenza
respiratori
syncyti
viru
may
involv
mechan
preferenti
bacteri
adher
wherea
individu
iga
defici
increas
respiratori
infect
igg
certain
igg
subclass
defici
recurr
respiratori
infect
igg
limit
invas
microorgan
epithelium
opson
complement
fixat
concentr
increas
hundredfold
respiratori
tract
presenc
infect
increas
vascular
permeabl
protect
respiratori
tract
microbi
invad
complex
process
involv
mani
immun
cell
dendrit
cell
b
tlymphocyt
neutrophil
macrophag
secretori
product
immunoglobulin
cytokin
opsonin
enzym
oxygen
metabolit
nonimmun
opsonin
surfact
fibronectin
fragment
possibl
creactiv
protein
recent
studi
indic
progranulin
autocrin
growth
factor
express
varieti
tissu
cell
type
play
protect
role
lung
immun
bacteri
pneumonia
elev
progranulin
level
observ
clinic
experiment
bacteri
pneumonia
mediat
host
defens
gramposit
gramneg
bacteri
pneumonia
healthi
mucosa
colon
complex
milieu
microorgan
exclus
aerob
anaerob
bacteria
probabl
play
import
protect
role
invad
pathogen
normal
microb
prevent
establish
invad
pathogen
microb
respiratori
epithelium
first
step
induc
infect
past
decad
mark
interest
research
role
normal
microbiom
respiratori
tract
health
diseas
facilit
modern
sophist
molecular
multiom
techniqu
recent
studi
human
microbiom
includ
respiratori
tract
demonstr
resid
microflora
much
abund
divers
previous
realiz
includ
mani
speci
noncultur
bacteria
virus
virom
fungi
protozoa
present
data
indic
microbiom
gut
lung
link
immun
cell
mediat
mayb
import
associ
pathogenesi
respiratori
diseas
bronchial
tract
harbor
complex
dynam
microbi
milieu
speci
overlap
oral
microbiom
lung
also
colon
airway
microbiota
resembl
microbiom
mouth
nostril
lower
densiti
studi
link
dysbiosi
respiratori
microbiom
asthma
chronic
lung
diseas
cystic
fibrosi
bronchiectasi
chronic
obstruct
pulmonari
diseas
copd
howev
data
yet
associ
acut
pneumonia
gener
believ
cap
occur
aspir
pathogen
microb
colon
nasopharynx
situat
defect
normal
airway
defens
incit
factor
may
play
role
develop
pneumonia
includ
preced
viral
upper
respiratori
tract
infect
seen
nearli
bacteri
cap
minor
infect
result
defect
mucociliari
function
clearanc
aspir
bacteria
allow
adher
pathogen
mucosa
quit
possibl
upper
respiratori
viru
infect
result
dysbiosi
commens
respiratori
microbiom
cigarett
smoke
similar
effect
airway
defens
associ
dysbiosi
resid
microbiota
although
numer
microorgan
caus
lung
involv
pneumonia
estim
sever
associ
cap
children
adult
clinic
practic
identif
etiolog
microb
cap
usual
achiev
case
sputum
cultur
often
nonspecif
difficult
interpret
contamin
oralpharyng
commens
blood
cultur
posit
adult
even
less
children
bacteri
pneumonia
urinari
antigen
detect
streptococcu
pneumonia
may
improv
sensit
compar
cultur
sensit
fals
posit
colon
children
recent
year
studi
appli
molecular
assay
virus
bacteria
microbi
diagnosi
result
indic
etiolog
cap
may
vari
age
children
year
age
cap
commonli
due
virus
mainli
respiratori
syncyti
viru
rsv
especi
absenc
lobar
consolid
effus
even
extens
test
pathogen
identifi
children
cap
recent
studi
children
year
age
hospit
cap
without
identifi
etiolog
asymptomat
control
metagenom
nextgener
sequenc
panvir
pcr
abl
identifi
put
pathogen
unidentifi
case
nasopharyng
oropharyng
swab
put
viral
pathogen
includ
human
parainfluenza
viru
human
bocaviru
coxsackievirus
rhinoviru
c
human
bocaviru
commonli
detect
viru
plausibl
virus
caus
upper
respiratori
tract
diseas
result
cap
bacteri
pathogen
although
cultur
pcr
bacteri
pathogen
obtain
endobronchi
secret
routin
obtain
metaanalysi
detect
virus
pcr
childhood
cap
pool
incid
mix
infect
rhinoviru
rsv
bocaviru
three
common
virus
childhood
cap
respiratori
virus
detect
patient
age
year
patient
year
children
age
year
estim
half
viral
infect
probabl
concurr
bacteri
infect
etiolog
infer
identifi
virus
upper
respiratori
tract
children
cap
still
unclear
although
higher
viral
load
microbi
etiolog
communityacquir
pneumonia
found
children
pneumonia
compar
control
virus
util
diagnos
viral
pneumonia
quantit
pcr
equivoc
still
opinion
expert
cap
children
radiograph
alveolar
infiltr
due
bacteria
predominantli
pneumonia
previou
studi
report
associ
upper
airway
densiti
pneumonia
pneumococc
pneumonia
nasopharyng
bacteri
load
pathogen
significantli
higher
viral
infect
compar
viral
infect
casecontrol
studi
seven
develop
countri
colon
densiti
pneumonia
upper
airway
compar
children
year
age
proven
pneumococc
pneumonia
control
pneumococc
colon
densiti
log
copiesml
strongli
associ
confirm
pneumococc
pneumonia
sensit
specif
suffici
accur
clinic
diagnosi
group
investig
also
assess
colon
densiti
upper
respiratori
tract
confirm
pneumonia
haemophilu
influenza
moraxella
catarrhali
staphylococcu
aureu
pneumocysti
jirovecii
associ
colon
densiti
log
copiesml
h
influenza
confirm
pneumonia
sensit
specif
respiratori
pathogen
adult
microbi
diagnosi
cap
convent
microbiolog
urin
antigen
detect
commerci
pcr
virus
two
prospect
studi
usa
low
yield
studi
fail
identifi
respiratori
pathogen
case
pneumococci
found
case
respiratori
virus
atyp
organ
case
one
studi
prospect
studi
hospit
patient
cap
netherland
use
similar
investig
techniqu
ad
realtim
pcr
atyp
organ
mycoplasma
pneumonia
legionella
pneumophila
coxiella
burnetii
chlamydophila
sp
identifi
pneumonia
c
burnetii
h
influenza
atyp
bacteria
includ
legionella
european
studi
use
advanc
microbiolog
techniqu
identif
pneumococcu
case
identif
pathogen
case
norway
bacteri
etiolog
found
virus
includ
viralbacteri
coinfect
prospect
studi
china
besid
viral
cultur
nucleic
acid
amplif
assess
pair
sera
antibodi
respons
viral
etiolog
establish
cap
review
metaanalysi
incid
viral
infect
adult
cap
incid
rang
lower
tract
sampl
associ
higher
viral
yield
three
main
virus
influenza
viru
rhinoviru
coronaviru
similar
review
investig
pool
proport
patient
viral
infect
similar
studi
obtain
lower
respiratori
sampl
proport
increas
recent
britain
adult
patient
confirm
pneumonia
admit
two
tertiarycar
hospit
cultur
comprehens
molecular
test
multiplex
realtim
pcr
respiratori
virus
bacteria
sputum
endotrach
aspir
case
etiolog
agent
identifi
molecular
test
compar
culturebas
method
bacteri
pathogen
detect
pcr
cultur
patient
receiv
antibiot
admiss
virus
present
case
codetect
bacteri
pathogen
surpris
h
influenza
common
bacteria
follow
pneumococcu
catarrhali
aureu
klebsiella
pneumonia
atyp
organ
question
mere
detect
pathogen
suffici
attribut
causal
unless
evid
acut
immun
respons
specimen
sputa
asept
collect
endotrach
secret
high
incid
h
influenza
could
repres
oropharyng
colon
nontyp
strain
high
preval
copd
high
proport
older
patient
year
age
low
preval
atyp
organ
mycoplasma
chlamydophila
pneumonia
surpris
patient
sever
pneumonia
requir
hospit
like
mildmoder
cap
receiv
ambulatori
treatment
would
higher
proport
atyp
bacteria
similar
smaller
studi
japan
use
convent
method
realtim
pcr
diagnosi
cap
n
sputa
nasopharyng
swab
molecular
method
detect
caus
organ
versu
convent
method
pneumonia
frequent
identifi
follow
h
influenza
pneumonia
pneumococcu
import
bacteri
caus
cap
respons
cap
mortal
sever
case
rate
detect
vari
rapid
diagnosi
pneumococc
etiolog
could
lead
initi
treatment
narrowspectrum
antibiot
penicillin
would
cost
save
decreas
risk
superinfect
clostridium
difficil
lower
rate
predispos
multiresist
bacteria
sputum
gram
stain
present
inexpens
rapid
easi
perform
test
underus
clinic
set
assist
diagnosi
treatment
cap
prospect
studi
patient
pneumonia
cap
util
sputum
gram
stain
assess
good
qualiti
sampl
sensit
specif
gram
stain
pneumonia
h
influenza
catarrhali
k
pneumonia
aureu
unfortun
patient
pneumonia
poor
qualiti
sputum
limit
overal
diagnost
valu
henc
simpl
test
routin
use
diagnosi
cap
whenev
purul
sputum
avail
detect
pneumococcu
cpolysaccharid
urin
immun
chromatographi
increasingli
use
evalu
patient
cap
larg
observ
multicent
prospect
studi
patient
admit
hospit
cap
pneumococc
infect
diagnos
case
diagnos
exclus
urinari
antigen
test
sensit
specif
respect
combin
differ
method
howev
appear
sensit
use
quantit
q
pcr
blood
sampl
multiplex
immunoassay
urin
antigen
multiplex
immunoassay
serolog
antibodi
respons
serotyp
abl
detect
pneumococcu
case
patient
convent
method
qpcr
blood
sampl
howev
sensit
blood
cultur
interpret
studi
util
comprehens
molecular
method
etiolog
diagnosi
cap
find
virus
pathogen
bacteria
nasopharyng
sputum
specimen
may
prove
causal
pneumonia
clearli
caus
upper
tract
infect
colon
without
produc
lower
respiratori
diseas
howev
absenc
specif
pathogen
these
assay
effect
exclud
etiolog
agent
sinc
nearli
cap
result
aspir
upper
airway
microb
combin
test
sputum
gram
stain
cultur
blood
cultur
urinari
antigen
antibodi
respons
microb
may
specif
reliabl
method
determin
causal
highli
sensit
provid
rapid
result
affect
manag
futur
research
focu
rapid
readili
avail
inexpens
test
etiolog
diagnosi
cap
could
use
emerg
depart
method
may
use
immunoassay
could
detect
variou
bacteri
pathogen
antigen
semiquantit
sputum
blood
urin
form
dipstick
similar
urinalysi
test
case
cap
diagnosi
straightforward
sinc
advent
chest
radiograph
signific
advanc
diagnost
method
typic
mild
case
cap
clinic
symptom
recent
cough
fever
presenc
chest
crackl
may
treat
empir
without
chest
xray
blood
test
howev
normal
chest
examin
present
cap
chest
radiograph
standard
investig
confirm
pneumonia
suspect
case
done
moderatesever
cap
even
presenc
typic
chest
find
defin
extent
lung
involv
assess
presenc
parapneumon
effus
possibl
empyema
presenc
pulmonari
cavit
abscess
presenc
necrot
pneumonia
restrict
etiolog
diagnosi
bacteria
usual
requir
longer
durat
therapi
diagnosi
cap
difficult
complic
case
often
sever
case
multiorgan
failur
dysfunct
requir
intens
care
situat
difficulti
lie
interpret
chest
xray
problem
aris
differenti
pneumonia
pulmonari
edema
hemorrhag
atelectasi
acut
respiratori
distress
syndrom
ard
computer
tomographi
ct
scan
may
may
abl
differenti
condit
bedsid
ultrasonographi
use
diagnos
pneumonia
less
reliabl
radiographi
sensit
rang
specif
ultrasound
use
defin
presenc
sever
associ
pleural
effus
investig
also
assess
valu
molecular
biomark
sever
ill
patient
differenti
cap
noninfecti
caus
lung
infiltr
studi
patient
admit
intens
care
unit
icu
suspect
cap
genomewid
transcript
profil
blood
leucocyt
investig
express
proinflammatori
antiinflammatori
pathway
similar
patient
without
cap
blood
concentr
biomark
procalcitonin
interleukin
il
interleukin
discriminatori
analysi
reveal
ratio
two
gene
best
distinguish
cap
nocap
ratio
provid
posit
predict
valu
neg
predict
valu
howev
clinic
util
manag
serious
ill
patient
question
studi
need
risk
cap
invas
pneumococc
infect
adult
increas
older
age
number
comorbid
cigarett
smoke
combin
proton
pump
inhibitor
ppi
commonli
prescrib
medic
highrisk
popul
also
may
add
risk
cap
systemat
review
studi
case
cap
report
increas
risk
cap
highest
risk
first
day
initi
ppi
cap
common
infecti
diseas
lead
hospit
icu
lead
caus
mortal
patient
infect
sever
sepsi
may
present
onethird
patient
present
cap
hospit
predictor
sever
sepsi
assess
factor
import
arriv
emerg
depart
ed
facilit
rapid
treatment
close
monitor
avoid
high
fatal
prospect
multicent
cohort
studi
hospit
cap
patient
present
sever
sepsi
comorbid
condit
cardiovascular
diseas
may
predispos
sever
sepsi
may
result
higher
mortal
morbid
previou
studi
indic
cap
associ
increas
cardiovascular
complic
multicent
prospect
cohort
patient
hospit
cap
variou
score
system
biomark
develop
identifi
sever
cap
assess
prognosi
mortal
risk
assist
physician
make
decis
hospit
icu
admiss
score
system
design
use
nonimmunosuppress
patient
commonli
use
score
system
score
base
five
easili
measur
factor
see
tabl
presenc
factor
given
score
maximum
initi
studi
patient
deriv
cohort
separ
valid
cohort
day
mortal
factor
base
data
suggest
cap
patient
score
could
treat
outpati
score
admit
hospit
score
assess
icu
care
howev
anoth
larg
studi
patient
cap
report
mortal
score
suggest
even
score
indic
hospit
admiss
healthi
person
without
factor
signific
comorbid
ill
could
treat
outpati
antibiot
recent
studi
howev
good
accuraci
predict
mortal
among
patient
cap
discharg
er
among
er
encount
threshold
sensit
specif
predict
mortal
neg
predict
valu
simplifi
version
without
blood
test
measur
blood
urea
nitrogen
bun
design
use
doctor
offic
assess
sever
cap
score
present
patient
refer
hospit
admiss
score
extens
evalu
found
good
predict
valu
patient
cap
pneumonia
sever
index
psi
assess
base
presenc
variabl
divid
five
strata
increas
risk
shortterm
mortal
present
lowrisk
patient
cumul
mortal
fall
class
iiii
wherea
patient
class
iv
v
higher
mortal
risk
although
sever
larg
studi
valid
predict
util
complex
calcul
less
user
friendli
predict
perform
similar
prospect
comparison
henc
commonli
use
ed
physician
assess
cap
sever
british
thorac
societi
nation
institut
health
care
excel
nice
guidelin
recommend
sever
assess
cap
bun
blood
urea
nitrogen
disposit
patient
base
total
score
treat
outpati
admit
hospit
patient
hospit
cap
risk
predict
use
assess
need
icu
care
mechan
ventil
mortal
monitor
creactiv
protein
crp
hospit
may
use
predict
respons
risk
death
retrospect
multicent
studi
patient
cap
admit
three
dutch
hospit
highest
mortal
risk
seen
patient
fail
demonstr
declin
crp
day
treatment
irrespect
actual
valu
initi
score
studi
valid
larger
prospect
studi
three
score
system
develop
identifi
sever
cap
hospit
need
icu
manag
includ
sever
communityacquir
pneumonia
score
scap
smartcop
infecti
diseas
societi
america
american
thorac
societi
idsaat
sever
criteria
see
tabl
three
system
util
combin
clinic
criteria
shock
alter
mental
state
respiratori
failur
routin
blood
test
arteri
blood
ga
result
scap
score
least
one
major
two
minor
criteria
superior
predict
progress
sever
pneumonia
valid
studi
show
scap
score
accur
predict
score
system
predict
icu
admiss
progress
sever
sepsi
treatment
failur
need
mechan
ventil
smartcop
score
system
assess
prospect
studi
episod
cap
requir
hospit
patient
year
old
factor
led
accrual
one
point
except
low
systol
blood
pressur
poor
oxygen
low
arteri
ph
subscrib
two
point
smartcop
score
point
identifi
patient
receiv
intens
respiratori
vasopressor
support
predict
smartcop
less
accur
younger
adult
year
age
fail
identifi
need
critic
measur
patient
age
group
idsaat
sever
system
base
two
major
criteria
nine
minor
criteria
one
major
criteria
septic
shock
requir
vasopressor
requir
mechan
ventil
univers
accept
selfevid
three
minor
criteria
indic
need
icu
manag
valid
studi
patient
cap
meet
major
criteria
found
minor
criteria
equival
smartcop
score
system
predict
need
mechan
ventil
vasopressor
support
icu
care
recent
investig
modifi
idsaat
minor
criteria
exclud
four
infrequ
variabl
leucopenia
hypothermia
hypotens
thrombocytopenia
ad
age
year
modifi
version
bestpredict
mortal
unclear
whether
use
predict
need
icu
care
vasopressorventil
support
variou
blood
biomark
studi
prognost
predictor
cap
includ
procalcitonin
pct
crp
proadrenomedullin
proadm
presepsin
copeptin
cortisol
pct
extens
studi
total
studi
pneumonia
patient
although
elev
pct
level
risk
factor
death
cap
particularli
patient
low
score
commonli
use
cutoff
ngml
low
sensit
identifi
patient
risk
die
systemat
review
metaanalysi
predict
valu
variou
biomark
cap
patient
demonstr
moderategood
accuraci
predict
mortal
clear
advantag
capspecif
score
standard
predict
score
appli
patient
seen
hospit
ed
cap
main
contenti
issu
whether
patient
score
admit
treat
outpati
may
reason
admit
patient
one
factor
age
year
alon
use
age
alon
admiss
support
evid
almost
everi
medic
ill
howev
patient
year
older
signific
comorbid
ill
underli
cardiovascular
diseas
admit
monitor
patient
admit
hospit
idsa
at
guidelin
mayb
appropri
use
decid
care
icu
although
scap
smartcop
score
suitabl
well
empir
treatment
cap
design
treat
common
bacteri
respiratori
pathogen
pneumonia
h
influenza
atyp
bacteria
pneumonia
cpneumonia
recent
etiolog
studi
suggest
larg
proport
cap
due
pct
threshold
discrimin
viral
bacteri
etiolog
high
sensit
specif
contenti
issu
empir
manag
cap
routin
coverag
atyp
bacteria
macrolid
pneumonia
c
pneumonia
infect
usual
associ
selflimit
cours
recoveri
wherea
north
american
guidelin
outpati
treatment
cap
list
macrolid
first
choic
european
guidelin
consid
macrolid
second
choic
penicillinallerg
patient
moreov
coverag
atyp
bacteria
routin
manag
cap
proven
benefici
systemat
review
trial
random
patient
advantag
found
regimen
cover
atyp
bacteria
major
outcom
testedmort
clinic
efficaci
macrolid
sole
therapi
cap
mayb
inadequ
cover
pneumococcu
preval
macrolid
resist
increas
current
although
clinic
signific
uncertain
patient
moderatesever
cap
hospit
north
american
european
guidelin
recommend
initi
broadspectrum
therapi
agent
often
ceftriaxon
macrolid
respiratori
quinolon
alon
macrolid
immunomodulatori
effect
antiinflammatori
properti
may
improv
outcom
even
pneumococc
infect
even
gramneg
sepsi
ventilatorassoci
pneumonia
clarithromycin
report
restor
immunoparalysi
improv
outcom
recent
systemat
review
antibiot
therapi
hospit
adult
cap
publish
sever
key
aspect
antibiot
therapi
summar
eight
observ
studi
show
antibiot
initi
within
h
hospit
arriv
associ
decreas
mortal
step
intraven
oral
therapi
patient
stabl
shorten
hospit
stay
without
affect
outcom
choic
empir
antibiot
outcom
mix
inconclus
six
eight
lowqual
observ
studi
patient
found
treatment
cap
tion
macrolid
associ
reduc
shortterm
mortal
monotherapi
three
largest
studi
retrospect
design
three
observ
mainli
retrospect
studi
found
reduc
mortal
quinolon
monotherapi
compar
monotherapi
howev
prospect
random
trial
result
confirm
superior
combin
macrolid
quinolon
monotherapi
first
trial
switzerland
adult
moderatesever
cap
admit
six
acut
care
hospit
random
monotherapi
macrolid
combin
mortal
icu
admiss
length
stay
recurr
pneumonia
within
month
differ
treatment
second
prospect
multicent
dutch
trial
patient
cap
admit
nonicu
ward
allot
one
three
treatment
clusterrandom
crossov
design
strategi
rotat
period
monotherapi
noninferior
strategi
macrolid
combin
quinolon
monotherapi
month
mortal
length
stay
complic
quinolon
use
given
oral
onset
patient
take
oral
medic
sinc
fulli
bioavail
idsa
guidelin
recommend
initi
intraven
therapi
sever
pneumonia
wellconduct
observ
studi
confirm
intraven
rout
necessari
sever
cap
durat
treatment
cap
well
establish
idsaat
guidelin
recommend
least
day
treatment
patient
stabl
afebril
h
british
guidelin
advic
day
mildmoder
day
moderatesever
cap
nice
guidelin
recommend
day
mild
day
moderatesever
cap
recent
multicent
random
trial
four
teach
hospit
spain
durat
antibiot
treatment
studi
hospit
patient
cap
day
treatment
intervent
group
stop
antibiot
afebril
h
one
capassoci
sign
instabl
durat
antibiot
control
group
determin
physician
signific
differ
outcom
two
group
thu
idsaat
guidelin
safe
implement
hospit
patient
cap
current
data
indic
amoxicillin
outpati
treatment
mildmoder
cap
day
prefer
therapi
macrolid
monotherapi
avoid
due
high
rise
resist
pneumonia
furthermor
moder
macrolid
resist
pneumonia
report
analysi
resist
mutat
gene
amoxicillinclavulan
acid
mayb
prefer
cover
strain
h
influenza
catarrhali
elderli
subject
copd
chronic
bronchiti
patient
admit
hospit
moderatesever
cap
requir
icu
care
treat
monotherapi
commonli
ceftriaxon
amoxicillinclavulan
acid
use
respiratori
quinolon
oral
whenev
pneumococcu
shown
etiolog
agent
penicillin
use
evid
outcom
advers
affect
penicillin
nonsuscept
rel
resist
strain
cap
even
bacteremia
patient
sever
cap
requir
icu
care
ceftriaxon
macrolid
quinolon
alon
suitabl
set
macrolid
use
l
pneumophila
infect
organ
exclud
sever
cap
high
mortal
despit
adequ
antibiot
therapi
thu
adjunct
therapi
studi
use
empir
tri
improv
outcom
combin
macrolid
macrolideresist
bacteria
form
adjunct
therapi
compar
studi
inflammatori
respons
patient
sever
nonsever
cap
use
guid
adjunct
therapi
one
studi
sever
cap
group
show
higher
plasma
level
proand
antiinflammatori
cytokin
contrast
lower
sputum
concentr
proinflammatori
cytokin
moreov
neutrophil
sever
cap
patient
show
reduc
respiratori
burst
activ
compar
nonsever
group
result
indic
patient
sever
cap
fail
mount
robust
local
inflammatori
respons
instead
produc
heighten
system
inflammatori
respons
suggest
statin
primarili
indic
dyslipidemia
cardiovascular
diseas
modul
effect
cytokin
cascad
could
use
sever
cap
previou
review
immunomodulatori
effect
statin
cap
experiment
clinic
studi
identifi
statin
attenu
pulmonari
inflamm
reduc
cytokin
releas
express
modul
neutrophil
function
protect
disrupt
lung
integr
observ
studi
suggest
decreas
mortal
due
cap
current
statin
user
random
studi
lack
random
doubleblind
placebocontrol
trial
simvastatin
cap
initi
spain
termin
enrol
patient
slow
enrol
howev
h
statin
differ
concentr
cytokin
compar
patient
placebo
thu
benefit
statin
cap
remain
unknown
corticosteroid
steroid
studi
antiinflammatori
effect
sever
cap
attempt
reduc
mortal
ard
need
mechan
ventil
icu
care
inconclus
result
although
steroid
shown
improv
outcom
decreas
risk
respiratori
failur
pneumocysti
pneumonia
fail
improv
outcom
major
definit
random
control
trial
patient
caus
sepsi
previou
review
topic
conclud
steroid
use
cap
insuffici
evid
benefici
effect
potenti
harm
sinc
two
random
placebocontrol
trial
adjunct
steroid
cap
report
first
studi
spain
random
patient
intraven
methylprednisolon
placebo
day
less
earli
treatment
failur
composit
end
adjunct
therapi
sever
cap
point
defin
studi
steroid
treat
group
differ
mortal
second
studi
switzerland
random
patient
either
prednison
mg
daili
placebo
day
prednison
shorten
time
clinic
stabil
day
without
increas
complic
improv
mortal
past
year
four
systemat
review
metaanalys
valu
steroid
cap
publish
first
report
ten
random
control
trial
rct
case
hospit
cap
review
mortal
decreas
severecas
subgroup
patient
requir
icu
care
length
icu
decreas
day
length
hospit
stay
day
second
review
trial
includ
patient
conclud
steroid
may
reduc
mortal
need
mechan
ventil
hospit
stay
day
includ
analysi
steroid
treatment
associ
reduc
ard
reduc
length
icu
stay
effect
mortal
none
four
studi
found
signific
advers
event
steroid
except
hyperglycemia
moderatesever
cap
adjunct
macrolid
benefici
random
studi
still
need
sever
case
risk
icu
manag
steroid
may
benefici
reduc
mortal
ard
mechan
ventil
sever
cap
result
conclus
thu
would
prematur
use
steroid
routin
sever
cap
pend
larger
rct
subgroup
patient
admit
hospit
recent
review
metaanalysi
steroid
hospit
patient
cap
analysi
case
six
trial
steroid
reduc
time
clinic
stabil
length
hospit
stay
day
reduc
mortal
increas
risk
hyperglycemia
caprel
rehospit
state
art
reminisc
data
steroid
sepsissept
shock
steroid
appear
effect
reduc
mortal
base
small
rct
proven
ineffect
larger
definit
trial
least
three
larg
trial
regist
clinic
trialsgov
expect
enrol
total
patient
schedul
complet
octob
provid
definit
data
use
steroid
cap
futur
trial
investig
effect
ad
nonsteroid
antiinflammatori
agent
nsaid
treatment
cap
recent
open
random
trial
hong
kong
patient
hospit
sever
influenza
pulmonari
infiltr
significantli
lower
mortal
shorter
hospit
stay
treatment
naproxenclarithromycin
day
oseltamivir
oseltamivir
group
receiv
betalactam
antibiot
past
year
mark
reduct
total
burden
mortal
pneumonia
children
year
age
occur
worldwid
attribut
number
factor
improv
healthcar
socialeconom
condit
low
earn
countri
major
contribut
due
increas
vaccin
measl
pertussi
pneumonia
h
influenza
type
b
conjug
vaccin
howev
similar
reduct
cap
realiz
adult
smoke
cessat
may
reduc
risk
cap
chronic
smoker
perman
cessat
difficult
achiev
world
health
organ
estim
billion
world
popul
smoke
smoke
strong
risk
factor
invas
pneumococc
diseas
bacteri
pneumonia
temper
countri
peak
incid
cap
occur
winter
peak
influenza
season
thu
univers
yearli
influenza
vaccin
may
decreas
incid
cap
children
adult
influenza
bacteri
pneumonia
previou
studi
shown
influenza
vaccin
effect
prevent
hospit
acut
respiratori
ill
associ
confirm
influenza
estim
rang
among
children
among
adult
adult
year
older
howev
studi
specif
assess
effect
influenza
vaccin
preval
cap
prospect
observ
multicent
studi
hospit
cap
year
four
us
site
patient
hospit
cap
among
children
adult
confirm
influenzaassoci
pneumonia
lower
odd
receiv
influenza
vaccin
indic
influenza
vaccin
reduc
cap
influenza
complic
includ
secondari
bacteri
pneumonia
introduct
subsequ
spneumonia
conjug
vaccin
children
resourcerich
countri
result
declin
pneumococc
pneumonia
children
adult
well
herd
protect
pneumococc
polysaccharid
vaccin
avail
year
recommend
mani
countri
highrisk
patient
efficaci
prevent
cap
debat
three
recent
review
metaanalysi
benefit
prevent
pneumococc
cap
adult
publish
inconsist
conclus
one
review
found
proof
prevent
pneumococc
cap
elderli
popul
anoth
studi
review
seven
random
trial
involv
subject
conclud
vaccin
provid
weak
protect
caus
pneumonia
third
review
howev
report
vaccin
effect
prevent
invas
pneumococc
diseas
cohort
studi
casecontrol
studi
lower
prevent
cap
reduct
trial
casecontrol
studi
effect
cohort
studi
howev
conjug
vaccin
appear
effect
adult
larg
placeborct
involv
adult
year
age
older
communityacquir
pneumonia
immun
trial
adult
capita
vaccin
assess
vaccin
efficaci
prevent
vaccinetyp
pneumococc
cap
prevent
invas
pneumococc
diseas
effect
prevent
cap
caus
effect
treatment
clearli
need
smoke
cessat
worldwid
prevent
lung
cancer
cardiovascular
diseas
copd
mani
associ
cancer
ill
includ
possibl
cap
although
univers
annual
influenza
vaccin
recommend
children
adult
rate
vaccin
countri
low
popul
improv
effect
long
last
influenza
vaccin
given
nasal
oral
rout
need
facilit
greater
complianc
herd
immun
meantim
physician
encourag
annual
influenza
vaccin
offer
elderli
highrisk
adult
cap
pend
develop
market
conjug
pneumococc
vaccin
reason
administ
well
sever
month
later
